Regeneron Q3 top line up 23%, earnings up 13%

Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 results:

Revenues: $2,048M (+23.2%); product sales: $1,238M (+20.7%).

Eylea sales in U.S.: $1,188M (+16.2%).

Sanofi/Bayer collaboration revenue: $707M (+35.7%).

Sanofi: Dupixent sales: $508M (+306.4%); Praluent: $34M (-7.5%).

Net income: $670M (+12.6%); non-GAAP net income: $762M(+12.9%); EPS: $5.86 (+13.3%); non-GAAP EPS: $6.67 (+13.6%).

2019 guidance: Sanofi revenue: $490M – 510M from $500M – 530M.

https://seekingalpha.com/news/3514280-regeneron-q3-top-line-23-percent-earnings-13-percent